Nanovibronix, Inc. (NASDAQ:FEED) Stock Short Interest Falls 81.6%

Nanovibronix, Inc. (NASDAQ:FEED) saw a significant decline in short interest in September. As of September 15th, there was short interest totaling 16,107 shares, a decline of 81.6% from the August 31st total of 87,719 shares. Currently, 2.0% of the company’s stock are short sold. Based on an average daily volume of 196,700 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on FEED shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research note on Tuesday, July 21st. Wall Street Zen raised Nanovibronix from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Nanovibronix Trading Down 17.3%

NASDAQ FEED traded down $0.09 during trading hours on Friday, reaching $0.41. 10,594 shares of the company traded hands, compared to its average volume of 406,886. The stock has a market capitalization of $374,220.00, a PE ratio of -0.00 and a beta of 1.38. Nanovibronix has a 12 month low of $0.36 and a 12 month high of $89.40. The company has a 50 day moving average of $3.73 and a two-hundred day moving average of $10.55.

Nanovibronix (NASDAQ:FEED) last released its earnings results on Monday, August 17th. The company reported ($23.76) earnings per share for the quarter. The company had revenue of $0.24 million during the quarter. Nanovibronix had a negative return on equity of 60.73% and a negative net margin of 1,093.61%.

Nanovibronix Company Profile

NanoVibronix, Inc is a medical device company focused on developing and commercializing noninvasive therapeutic devices that use low-intensity surface acoustic wave technology. Its products are designed to support pain management, wound care and other clinical applications.

The company’s product portfolio has included PainShield, a wearable therapeutic ultrasound device intended to provide localized pain relief, and WoundShield, a device designed to support wound-care treatment. NanoVibronix has also developed UroShield, which is intended for the management of urinary discomfort and related conditions.

NanoVibronix has served healthcare providers and patients in the United States and international markets through medical distribution and sales channels.